Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meniere Disease
Reports summarize Meniere disease research from University of Sao Paulo
June 8th, 2009
According to recent research from Sao Paulo, Brazil, "Betahistine at oral doses of 16 mg tid and 24 mg bid provides similar efficacy and tolerability in the treatment of vertigo in patients with Meniere's disease. To compare the efficacy and tolerability of betahistine 16 mg tid and 24 mg bid in the treatment of vertigo in patients with Meniere's disease." "This was a randomized, open-label study of 120 consecutive patients with well-established Meniere's disease treated with betahistine 16 mg tid or 24 mg bid for 24 weeks. Treatment efficacy, assessed by clinical outcome level in terms of severity, frequency and duration of vertigo spells, was evaluated at baseline and...
Source: Biotech Business Week (2009-06-08)
|
